Z-2181-200 ZytoLight SPEC NRG1 Dual Color Break Apart Probe (200 μl)
designed to detect translocations involving the chromosomal region 8p12 harboring the NRG1 (neuregulin 1, a.k.a. HGL or GGF) gene.
Generally, NRG1 rearrangements in lung adenocarcinomas of never smokers were found to result in the fusion of CD74 to the EGF-like domain of NRG1. NRG1 constitutes a good candidate for potential therapeutic applications e.g. in relation to lung tumor subtypes with so far no effective treatment.
Z-2189-200 ZytoLight SPEC BRAF Dual Color Break Apart Probe (200 μl)
designed for the detection of rearrangements involving the chromosomal region 7q34 harboring the BRAF (B-Raf proto-oncogene, serine/threonine kinase, a.k.a. BRAF1, NS7) gene.
Various BRAF translocations were observed in melanocytic nevi, pilocytic astrocytomas, malignant melanoma, prostate and gastric cancer.
In vitro studies have shown a sensitivity of SND1-BRAF-transformed cells to treatment with a MEK inhibitor.
Z-2191-200 ZytoLight SPEC BRAF/CEN 7 Dual Color Probe (200 μl)
is designed for the detection of amplifications involving the chromosomal region 7q34 harboring the BRAF gene (B-Raf proto-oncogene, serine/ threonine kinase).
Colorectal carcinoma or melanoma patients with BRAF V600E mutation were found to acquire resistance to MEK and BRAF inhibitors through amplification of the mutated BRAF gene. Hence, detection of BRAF amplifications by Fluorescence in situ Hybridization may be of therapeutic relevance for these cancer patients.
Z-2193-200 ZytoLight SPEC KMT2A Dual Color Break Apart Probe (200 μl)
designed to detect translocations involving the chromosomal region 11q23.3 harboring the KMT2A (previous gene name: MLL) gene.
Translocations involving the KMT2A gene are commonly identified in 5-6 % of all acute myeloid leukemias (AML), and 5-10 % of all acute lymphoblastic leukemias (ALL). Between 1-15 % of cancer patients treated with DNA topoisomerase II inhibitor develop therapy-related leukemia (t-AML) associated with KMT2A translocations.
Generally, the presence of KMT2A rearrangements in patients with acute leukemia indicates a less favorable prognosis.
Z-2195-200 ZytoLight SPEC VEGFA/CEN 6 Dual Color Probe 200 μl
designed for the detection of amplifications involving the chromosomal region 6p21.1 harboring the VEGFA gene. VEGFA gene amplifications occur in colorectal cancers and result in a highly aggressive disease.
Additionally, hepatocellular carcinoma (HCC) patients with VEGFA gain responded better to a multi-kinase inhibitor (sorafenib) that blocks, i.a., receptors of the VEGFA protein, resulting in improved survival of the patients.